Adipotide and Tirzepatide Interaction: Monitor | Peptide Database

FDA-approved for the treatment of primary hyperlipidemia and mixed dyslipidemia. Pitavastatin 2-4 mg provides clinically meaningful LDL reduction comparable to moderate-intensity atorvastatin or rosuvastatin. Particularly well-suited for patients on complex medication regimens where drug interactions are a concern. Used off-label to manage lipid disturbances caused by anabolic steroid cycles. Its primary advantage in this context is the absence of CYP3A4 interactions, meaning it can be safely co-administered with compounds, ancillaries, and other medications without dose adjustments or concerns about altered statin levels. The relatively stronger HDL-raising effect compared to other statins is an additional benefit given that HDL suppression is often the most resistant lipid abnormality during AAS use. The preferred statin choice for individuals with pre-existing insulin resistance, metabolic syndrome, or borderline glucose tolerance. The J-PREDICT trial showed pitavastatin actually reduced the incidence of new-onset diabetes by 18% compared to placebo, in contrast to other statins which modestly increase diabetes risk. This is particularly relevant for AAS users running compounds that affect glucose metabolism such as growth hormone or certain oral steroids. Appropriate for cardiovascular risk reduction in individuals with dyslipidemia and additional risk factors. While pitavastatin lacks the large-scale dedicated cardiovascular outcomes trial data that rosuvastatin and atorvastatin have (JUPITER, ASCOT), its class-effect benefits are well established and supported by the long-term LIVES study data from Japan. The statin of choice when drug interaction potential must be minimized. Especially relevant for individuals taking azole antifungals, macrolide antibiotics, protease inhibitors, or other CYP3A4 inhibitors that would significantly increase blood levels of atorvastatin or simvastatin. In the AAS context, this is advantageous for users running multiple compounds with hepatic metabolism.

Join others researching Telmisartan — share findings, ask questions, and learn from real experiences Telmisartan is an angiotensin II receptor blocker (ARB) originally developed for the treatment of hypertension and cardiovascular risk reduction. FDA-approved since 1998 and marketed as Micardis, it has become the preferred ARB among performance-enhancing drug users and anabolic steroid communities due to its long half-life, strong evidence for organ protection, and unique partial PPAR-gamma agonist activity. Unlike other ARBs, telmisartan activates peroxisome proliferator-activated receptor gamma (PPAR-gamma) at clinically relevant doses, conferring metabolic benefits that extend beyond blood pressure reduction. Anabolic androgenic steroids (AAS) are well-documented to elevate blood pressure, promote left ventricular hypertrophy, accelerate atherosclerosis, and impair renal function -- making proactive cardiovascular protection an essential component of harm reduction. Telmisartan addresses these concerns with once-daily dosing, 24-hour blood pressure coverage, and a favorable side effect profile that does not impair exercise performance or recovery. Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from exerting its vasoconstrictive, aldosterone-secreting, and pro-fibrotic effects. By antagonizing AT1, telmisartan lowers systemic vascular resistance and blood pressure while simultaneously reducing pathological cardiac and vascular remodeling. This is particularly relevant for AAS users, where supraphysiological androgen levels stimulate the renin-angiotensin-aldosterone system (RAAS) and promote myocardial fibrosis and left ventricular hypertrophy. Telmisartan also has the longest half-life of any ARB (approximately 24 hours), providing consistent receptor blockade throughout the dosing interval. Its unique partial agonism of PPAR-gamma -- a nuclear receptor involved in glucose and lipid metabolism -- distinguishes it from other ARBs. PPAR-gamma activation enhances insulin sensitivity, improves adiponectin secretion, reduces visceral fat accumulation, and exerts anti-inflammatory effects. Additionally, telmisartan demonstrates nephroprotective properties by reducing intraglomerular pressure and proteinuria, and has been shown in the ONTARGET trial to provide cardiovascular protection comparable to the ACE inhibitor ramipril in high-risk patients.